Skip to search formSkip to main contentSkip to account menu

Canfosfamide

Known as: (2R)-L-gamma-Glutamyl-3-((2-((bis(bis(2-chloroethyl)amino)phosphinyl)oxy)ethyl)sulfonyl)-L-alanyl-2-phenylglycine 
A modified glutathione analogue and nitrogen mustard prodrug, with potential antineoplastic activity. Canfosfamide is selectively activated by… 
National Institutes of Health

Related topics

Related topics

2 relations

Narrower (1)

TER 286
canfosfamide HCl

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Transparency in interim monitoring.
TO THE EDITOR: Most phase III randomized clinical trials (RCT) in oncology are designed to change clinical practice by… 
Review
2011
Review
2011
New emerging drugs targeting the genomic integrity and replication machinery in ovarian cancer
IntroductionOvarian cancer is a difficult to treat cancer entity with a high relapse rate. After initial surgery and chemotherapy… 
Review
2009
Review
2009
Randomized phase III study of canfosfamide (C, TLK286) plus pegylated liposomal doxorubicin (PLD) versus PLD as second-line therapy in platinum (P) refractory or resistant ovarian cancer (OC).
5552 Background: Canfosfamide (C) is a glutathione analog prodrug activated by glutathione S-transferase P1-1. C is synergistic… 
2009
2009
Canfosfamide formulation and manufacturing method thereof
Review
2007
Review
2007
Phase 3 Study: Canfosfamide (C, TLK286) plus carboplatin (P) vs liposomal doxorubicin (D) as 2nd line therapy of platinum (P) resistant ovarian cancer (OC)
LBA5529 Background: Canfosfamide (C) is a novel glutathione analog prodrug activated by glutathione S-transferase P1–1. C has… 
2007
2007
FDA halts canfosfamide trials
  • 2007
  • Corpus ID: 195107316
2007
2007
Canfosfamide Disappoints in Ovarian Cancer Trials
2007
2007
The recent full clinical hold placed on trials of canfosfamide [Telcyta]* has been converted to a partial hold by the US FDA
  • 2007
  • Corpus ID: 195171875
2005
2005
Canfosfamide and manufacturing method and manufacturing intermediates salt thereof, pharmaceutical compositions comprising the intermediate and its use as an anti-cancer agent
Canfosfamide and manufacturing method and manufacturing intermediates salt thereof, pharmaceutical compositions comprising the… 
2004
2004
Canfosfamide combinations promising in ovarian cancer
  • 2004
  • Corpus ID: 195152341
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)